Bridget Simonson
About Bridget Simonson
Bridget Simonson is a Research Scientist I at the Broad Institute of MIT and Harvard, specializing in cell signaling pathways and novel therapeutic targets. She has a background in cardiovascular research and extensive experience in single-nucleus RNA sequencing and in vivo mouse models.
Current Position at Broad Institute
Bridget Simonson serves as a Research Scientist I at the Broad Institute of MIT and Harvard. She has held this position since 2020, contributing to various research initiatives. Her work focuses on advancing potential therapeutics aimed at improving patient outcomes. Simonson's expertise in cell signaling pathways and novel therapeutic targets plays a crucial role in her research efforts.
Previous Experience at Beth Israel Deaconess Medical Center
Prior to her current role, Bridget Simonson worked as a Post Doctoral Fellow at the Beth Israel Deaconess Medical Center from 2011 to 2016. During her five years there, she was affiliated with the Cardiovascular Research Institute in Boston, MA. This experience allowed her to deepen her understanding of cardiovascular research and develop her skills in cellular and molecular biology.
Teaching Experience at Victoria University of Wellington
Bridget Simonson was a Teaching Assistant at Victoria University of Wellington from 2008 to 2011. Over her three years in this role, she supported students in their studies of cell and molecular biology. This position provided her with valuable experience in academic instruction and student engagement.
Education and Academic Qualifications
Bridget Simonson earned her Bachelor of Science (BSc) with honors in Cell/Cellular and Molecular Biology from Victoria University of Wellington, completing her studies from 2004 to 2008. She continued her education at the same institution, obtaining a Doctor of Philosophy (PhD) in the same field from 2008 to 2011. Her academic background laid the foundation for her research career.
Research Specializations and Skills
Bridget Simonson specializes in cell signaling pathways and novel therapeutic targets. She possesses expertise in single-nucleus RNA sequencing (snRNAseq) and is skilled in microscopy techniques relevant to cell biology research. Additionally, she has extensive experience with in vivo mouse models, which enhances her research capabilities in developing therapeutic interventions.